This is a pivotal time for Braveheart. Growing prospects at Kirkstall, Paraytec and Gyrometric continue to excite the Board, while the investment portfolio, combined with our substantial cash continues to provide solid underpinning to our balance sheet
Trevor E Brown, chief executive
What Braveheart Investment Group does:
Braveheart Investment Group PLC (LON:BRH) is an AIM-listed firm that provides funding and advisory services to small and medium-sized enterprises (SME).
Formed in 1997 as an investment syndicate, it now specialises in four areas – equity financing, debt financing, advisory services and fund management.
Braveheart invests in businesses through its many funds including the Finance Yorkshire Equity Fund, Strathclyde Innovation Fund and Lachesis Seed Fund.
The group, which floated on the London Stock Exchange in 2007, also invests on behalf of high net worth individuals, family offices, institutional investors and public sector organisations across the UK and Europe.
The company has about £71mln of funds under management with its portfolio spanning a number of sectors including healthcare equipment and services, travel and leisure, technology hardware and equipment, software and computer services, electronic and electrical equipment, and pharmaceuticals and biotechnology.
What it owns
In a portfolio update on 7 June 2019, Braveheart said it now holds five strategic investments in its portfolio alongside other historical investments.
These included biotechnology firm Kirkstall, UV light detection group Paraytec, propeller and rotating shaft monitoring group Gyrometric Systems, microscope imaging firm PhaseFocus and Sentinel Medical, a spin out of Paraytec developing technology to detect cancer cells in urine.
On 8 July, the company said that it had also acquired a 33% stake in Pharm2Farm Limited (P2F), a plant nutrients firm.
• Announcing the acquisition of its stake in P2F, Braveheart also said it was in negotiations to increase its holdings to 54% by way of a working capital investment
• In April, the company said it had disposed of its fund management arm Viking for £110,000 upfront with up to £170,500 to follow once a performance fee for an outstanding fund management contract was agreed
• In the first half of the current financial year, Braveheart made a profit before tax of £113,000 on revenue of £509,000, compared with a profit before tax of £191,000 on revenue of £397,000 the year before
At the first half results, Braveheart said, “the investment portfolio, combined with substantial cash, continues to provide a solid underpinning to our balance sheet, and developments in our fund management business offer a new source of fund management revenue in the next financial year”.
With the shares trading around 10.8p as of 8 July 2019, Braveheart carries a market cap of £2.6mln.